Pemvidutide
Also known as: ALT-801
Profile at a glance
| Attribute | Value |
|---|---|
| Sponsor | Altimmune |
| Mechanism | Balanced 1:1 GLP-1 + glucagon dual agonist |
| Administration | Once-weekly subcutaneous injection |
| Peak weight loss | ~15.6% at 48 weeks (MOMENTUM, 2.4 mg) |
| Status | Phase 2; FDA Breakthrough Therapy for MASH (Jan 2026); Phase 3 MASH planned |
Deep dive
What Is Pemvidutide? Altimmune's GLP-1/Glucagon Dual Agonist for Weight Loss and MASH →Altimmune's balanced GLP-1/glucagon dual agonist — 15.6% weight loss, 54.7% liver fat reduction, FDA Breakthrough Therapy Designation for MASH.
See all drug profiles in the drug profiles hub or compare drugs head-to-head in the comparisons hub.